Dermisonics, Inc.

IRVINE, Calif., April 6 /PRNewswire-FirstCall/ -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB - News), a medical device company focused on the development of painless, needle-free drug-delivery technology, has begun recruiting recipients to proceed with a planned Human Pilot Trial-2 on its U-Strip(TM) delivery system for use with insulin. This phase is being carried out on an initial group of Type-2 adult diabetics, which the Company believes represents the larger population of diabetics who could immediately benefit from this technology.

Comment - I've been investing in delivery technologies for years. The multilple platforms reduces the risk here, I would love to see their bioavailabilitty data for the insulin delivery compared to subcutaneous injection. This one could be a sleeper.